MAPT and Dravet syndrome: for DS, the findings here suggest that markers of neurodegeneration and glial activation (NfL, GFAP) are in keeping with meta‐analyses showing their association with disease progression, and that they may rise concurrently with, or slightly prior to, detectable increases in tau pathology.6, 53, 58